These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28155940)

  • 1. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
    Sui J; Cui Y; Cai H; Bian S; Xu Z; Zhou L; Sun Y; Liang J; Fan Y; Zhang X
    Nanoscale; 2017 Feb; 9(8):2755-2767. PubMed ID: 28155940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Delivery of DOX to Nuclei of Hepatic Carcinoma Cells in the Subcutaneous Tumor Model Using pH-Sensitive Pullulan-DOX Conjugates.
    Li H; Cui Y; Sui J; Bian S; Sun Y; Liang J; Fan Y; Zhang X
    ACS Appl Mater Interfaces; 2015 Jul; 7(29):15855-65. PubMed ID: 26140410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
    Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
    Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
    Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
    Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
    J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting.
    Li H; Bian S; Huang Y; Liang J; Fan Y; Zhang X
    J Biomed Mater Res A; 2014 Jan; 102(1):150-9. PubMed ID: 23613258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
    Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
    Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
    Malarvizhi GL; Retnakumari AP; Nair S; Koyakutty M
    Nanomedicine; 2014 Nov; 10(8):1649-59. PubMed ID: 24905399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
    Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
    Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
    Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pH-sensitive nano drug delivery system derived from pullulan/doxorubicin conjugate.
    Lu D; Wen X; Liang J; Gu Z; Zhang X; Fan Y
    J Biomed Mater Res B Appl Biomater; 2009 Apr; 89(1):177-83. PubMed ID: 18777581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
    Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
    J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
    Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
    Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin.
    Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY
    Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.